Executive Summary

Adquey is best understood as a new entrant in an established nonsteroidal topical category, rather than as a reset of atopic dermatitis treatment. Its label is broad across adults and children from age two, and its risk-management profile is comparatively simple.

The more consequential story is regulatory. FDA accepted a package centered on two positive Japanese pivotal trials, supported by a smaller multinational study, even though a planned U.S. Phase 3 trial stopped early and did not show a treatment difference. The decision illustrates how foreign pivotal data can support U.S. approval when FDA can establish relevance to the intended population and explain contradictory or incomplete evidence.

Commercial differentiation will depend less on mechanism novelty than on execution. Adquey must compete with established topical PDE4 inhibitors, once-daily nonsteroidal creams, a topical JAK inhibitor, and an expanding group of biologic and oral systemic therapies.

Approval at a Glance

FDA approved Adquey (difamilast) ointment, 1%, on February 12, 2026, for topical treatment of adults and pediatric patients two years of age and older with mild-to-moderate atopic dermatitis. The product is applied as a thin layer twice daily. The label lists no contraindications, and nasopharyngitis is the only adverse reaction reported in at least 1% of treated subjects. 12

Difamilast inhibits phosphodiesterase 4, increasing intracellular cyclic adenosine monophosphate and reducing production of multiple cytokines and chemokines. FDA nevertheless states that the specific mechanism by which topical difamilast produces its therapeutic effect is not well defined. 23

An Approval More Than a Decade in the Making

Difamilast was discovered by Otsuka, which opened U.S. IND 112973 in October 2011. U.S. sponsorship later transferred to Medimetriks in 2016 and to Acrotech in 2021. In parallel, Japan approved difamilast as Moizerto in September 2021 in 1% and 0.3% ointment strengths for adults and children two years of age and older. 34

The U.S. program required repeated alignment on endpoint definition and pediatric safety monitoring. At the 2018 end-of-Phase 2 meeting, FDA and the sponsor aligned on the 1% dose, Week 4 efficacy assessment, and the broad IGA success concept, but FDA continued to press for a more discriminating definition of “almost clear” and for prospective monitoring of depression and suicidality. 3

In 2020, the sponsor proposed relying on one U.S. Phase 3 trial plus the completed Japanese pivotal studies. FDA said the Japanese trials could be supportive if their design and analysis were adequate, while identifying uncertainty around the U.S. safety database and psychiatric monitoring. The first special protocol assessment submission for the U.S. trial did not reach agreement in 2021; agreement followed in May 2022 after revisions. 3

The SPA-agreed U.S. Phase 3 trial MEDI-MM36-301 was designed to enroll approximately 336 patients two years of age and older, randomized 2:1 to difamilast 1% ointment or vehicle for four weeks. The sponsor terminated the study in July 2023 after enrolling 153 patients, stating that the decision was for business reasons and not for reasons related to safety. The FDA review does not identify an interim futility finding or a prespecified efficacy stopping rule as the reason for termination. 3

The available efficacy result was not merely statistically nonsignificant. FDA’s analysis found Week 4 IGA success in 11 of 94 difamilast-treated patients (11.7%) and 7 of 59 vehicle-treated patients (11.9%), an estimated difference of -0.2 percentage points with a 95% confidence interval of -13.2 to 9.0 and p=0.702. The point estimate was therefore essentially null, although the incomplete enrollment prevented the trial from supplying the evidentiary value planned in the agreed design. 3

After the trial ended, the finalized statistical analysis plan stated that it would not be used to support efficacy and that the protocol-defined efficacy analyses, statistical testing, subgroup analyses, and per-protocol analysis would not be performed; efficacy listings would be provided instead. Acrotech then submitted the NDA without a pre-NDA meeting and declined FDA requests to provide an efficacy analysis, maintaining that the completed Japanese Phase 3 trials and multinational Phase 2 trial established efficacy. FDA performed its own analysis from the submitted data. 3

How FDA Resolved the Evidence Package

The efficacy endpoint across the key studies was IGA success at Week 4, defined as an Investigator’s Global Assessment score of clear or almost clear with at least a two-grade improvement from baseline. Both Japanese pivotal trials met this endpoint for difamilast 1%, with absolute differences from vehicle of 25.9 and 28.7 percentage points. 3

The multinational Phase 2 study conducted in the United States, Australia, and Poland was smaller and produced a lower response rate than the Japanese pivotal trials, but it remained statistically positive. FDA treated it as important supportive evidence because it included U.S. participants and offered a more directly relevant estimate of potential U.S. treatment effect. 3

The U.S. Phase 3 result was negative on its face, not simply an underpowered miss: response rates were virtually identical and the estimated treatment difference was -0.2 percentage points. Reduced enrollment limited precision and interpretability, but it does not by itself explain an observed point estimate that was essentially zero. 3

At the same time, FDA did not treat MEDI-MM36-301 as a definitive completed negative pivotal trial. The sponsor had terminated it for business reasons after less than half of planned enrollment, and the study was not completed or analyzed according to the original efficacy plan. FDA concluded that early termination substantially limited meaningful interpretation and that the result did not preclude a finding of substantial evidence of effectiveness based on the completed positive studies. 3

FDA’s generalizability assessment was explicit. The agency noted differences in diagnostic criteria, IGA definitions, baseline disease mix, investigator training, and observed effect size across regions. It nonetheless concluded that the Japanese findings could be extrapolated to U.S. patients based on the totality of disease, pharmacokinetic, safety, and supportive multinational efficacy evidence. FDA also required the multinational Phase 2 results to appear in labeling so prescribers could see the smaller treatment effect observed outside Japan. 32

A Favorable Label, With a Focused Pediatric Obligation

FDA’s controlled safety pool included 429 participants treated with difamilast 1%, while the long-term open-label pool included 857 treated participants. The long-term studies evaluated treatment for up to 52 weeks. In the two pivotal Japanese trials pooled for labeling, nasopharyngitis occurred in 6% of difamilast-treated participants and 4% of vehicle recipients. 32

The review did not identify a weight-loss signal characteristic of systemic PDE4 inhibition. Psychiatric findings were also broadly reassuring, with no reported suicidal ideation or behavior events, but FDA cautioned that the evidence was limited because only the terminated U.S. Phase 3 study used systematic prospective psychiatric assessments. FDA concluded that routine pharmacovigilance and labeling were sufficient and that a REMS was not warranted. 3

The label’s simplicity is strategically relevant but should not be overstated. It contains no contraindications and no warnings and precautions section, yet this does not establish comparative superiority to other topical therapies. The available evidence does not include a head-to-head trial against another approved nonsteroidal topical product. 23

The required pediatric study addresses the age group below the approved two-year threshold and must be conducted in the United States. Its design also reflects the review’s residual concerns about systemic exposure under maximal use and the limited direct U.S. evidence in the youngest patients. 13

The Direct Competition Is Topical and Nonsteroidal

Adquey enters a topical treatment framework in which moisturizers, topical corticosteroids, topical calcineurin inhibitors, crisaborole, and roflumilast all have established guideline support. Its most direct branded competition is not a single product, but a set of nonsteroidal options differentiated by mechanism, age range, dosing frequency, formulation, warnings, and payer access. 56789

Adquey’s clearest label-level advantages are its absence of contraindications and warnings, coverage from age two, and a generally limited adverse-reaction profile. Its practical disadvantages include twice-daily administration when Zoryve and Vtama are once daily, plus an age floor that is higher than Eucrisa’s three-month indication. Whether these differences translate into better persistence, access, or adoption is not established. 2678

Cross-trial percentages should not be used to rank these products. Their programs differ in populations, endpoint scales, study duration, rescue rules, background therapy, and statistical handling. The prescribing information for these products also cautions that adverse-reaction rates from separate trials are not directly comparable. 36789

The Broader Market Has Shifted Toward Targeted Systemic Therapy

The broader market has moved well beyond topical therapy. For moderate-to-severe disease inadequately controlled with topical prescriptions, FDA-approved options include biologics directed at IL-4 receptor alpha, IL-13, or IL-31 receptor signaling, along with oral JAK inhibitors. These products address a different severity and treatment-intensity segment than Adquey, but they shape expectations for disease control and influence when clinicians escalate beyond topical management. 101112131415

For Adquey, the strategic question is therefore not whether it can displace advanced systemic therapy in severe disease. It is whether it can earn a durable place before escalation, particularly among patients and prescribers seeking a nonsteroidal topical with a straightforward label. The evidence base does not establish where Adquey should be sequenced relative to other branded topicals. 251014

Failures and Setbacks That Define the Category

Atopic dermatitis development has produced distinct forms of failure: inadequate efficacy, incomplete execution, and regulatory delay unrelated to the clinical package. Adquey’s own program contains the most relevant example. MEDI-MM36-301 generated a nominally negative result with essentially no treatment separation, not merely a loss of statistical power from reduced enrollment. Yet because the sponsor stopped the trial for business reasons after enrolling 153 of 336 planned patients and did not complete the original efficacy analyses, FDA considered the study inconclusive rather than dispositive. 3

These cases should not be conflated. MOR106 was an efficacy futility outcome, the difamilast U.S. study was a nominally negative but incomplete execution outcome, and lebrikizumab encountered a manufacturing-related regulatory delay that was later resolved. The distinction matters because each failure mode demands a different development response. 3161718

Commercial Read-Through

Adquey’s U.S. opportunity will be determined by execution against established products rather than by first-in-class status. It is the third FDA-approved topical PDE4 option for atopic dermatitis after Eucrisa and Zoryve, and it enters alongside Vtama and Opzelura as additional nonsteroidal alternatives. 36789

In May 2026, Aurobindo management said a separate dermatology team and supporting infrastructure would be built for Adquey because the company’s existing commercial presence was in oncology and the eczema market would be competitive. In that discussion, management did not specify a first-commercial-shipment date, U.S. list price, formulary position, or uptake metrics. 19

The product’s most credible positioning is a combination of a clean label, pediatric use from age two, nonsteroidal mechanism, and prior postmarketing experience in Japan. The counterweights are twice-daily use, several established branded alternatives, and residual uncertainty about the magnitude of treatment effect in U.S. practice. No source establishes comparative efficacy, superior adherence, pricing advantage, or preferred formulary status. 2346789

Conclusion

Adquey’s approval is more instructive than its mechanism alone suggests. FDA accepted a globally assembled evidence package, confronted an unfinished U.S. trial directly, and articulated why the positive Japanese pivotal evidence remained applicable to U.S. patients.

The approval also shows the limits of regulatory success as a commercial differentiator. Adquey has a favorable label and a legitimate place in mild-to-moderate disease, but it must compete on dosing experience, access, prescriber confidence, and execution in a market with multiple nonsteroidal topicals and increasingly effective systemic options.

The development lesson is clear: foreign pivotal data can carry substantial weight, but only when trial quality, endpoint interpretability, pharmacology, safety, and population relevance are addressed as an integrated evidence problem.